Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases
Top Cited Papers
- 10 February 2017
- news
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (4), 1247-1261
- https://doi.org/10.1021/acs.jmedchem.6b01751
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Structural Basis of RIP1 Inhibition by NecrostatinsStructure, 2013
- The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others?MedChemComm, 2012
- A novel role for RIP1 kinase in mediating TNFα productionCell Death & Disease, 2012
- Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitisNature, 2011
- The Dual Functions of Receptor Interacting Protein 1 in Fas-Induced Hepatocyte Death During SepsisShock, 2011
- Necroptosis as an alternative form of programmed cell deathCurrent Opinion in Cell Biology, 2010
- Design, synthesis and selection of DNA-encoded small-molecule librariesNature Chemical Biology, 2009
- Identification of RIP1 kinase as a specific cellular target of necrostatinsNature Chemical Biology, 2008
- Structure–activity relationship study of novel necroptosis inhibitorsBioorganic & Medicinal Chemistry Letters, 2005
- A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell DeathScience, 2004